Abstracts - PAGE Meeting (Population Approach Group Europe)

← Back to filters

Abstracts (51)

I-11Linda Franken

Pharmacokinetics of midazolam and its metabolites in terminally ill adult patients

Wednesday 10:20-11:40

I-17Peter Gennemark

Unravelling the pharmacokinetic interaction of ticagrelor and MEDI2452 (ticagrelor-antidote) using mouse data

Wednesday 10:20-11:40

I-22Anais Glatard

Influence of UGT2B7 polymorphism on varenicline clearance in a cohort of smokers from the general population

Wednesday 10:20-11:40

I-24Bojana Golubovic

Population modelling of sirolimus data available from routine therapeutic drug monitoring

Wednesday 10:20-11:40

I-34Janelle Hajjar

Modeling Duchenne muscular dystrophy disease progression as assessed by the 6-minute walk test

Wednesday 10:20-11:40

I-35Nayoung Han

Dose estimation based on population pharmacokinetic/pharmacogenetic modeling for enteric-coated mycophenolate sodium in kidney transplant recipients

Wednesday 10:20-11:40

I-38Paul Healy

Model-based dose selection of tocilizumab for the prevention of reperfusion injury.

Wednesday 10:20-11:40

I-39Michael Heathman

A Categorical Time Course PKPD Model Describing the Effect of Ixekizumab on Improvement from Baseline in Psoriasis Area and Severity Index (PASI) score in Patients with Moderate to Severe Plaque Psoriasis

Wednesday 10:20-11:40

I-48Manuel Ibarra

Pharmacokinetic characterization of naphtalophos in lambs by modelling blood acetylcholinesterase activity, a K-PD model

Wednesday 10:20-11:40

II-01Khaled Abduljalil

Simcyp Simulator within the DDMoRe Interoperability Framework – Proof of Concept Cases

Wednesday 15:10-16:30

II-02João Abrantes

Population pharmacokinetic analysis of factor VIII activity following treatment with moroctocog alfa in moderate to severe haemophilia A subjects

Wednesday 15:10-16:30

II-14Violeta Balbas-Martinez

Target evaluation for Inflammatory Bowel Disease (IBD) using a Systems Pharmacology model

Wednesday 15:10-16:30

II-25Charlotte Bon

A target mediated cellular uptake model to assess the asialogycoprotein receptor shuttle capacity in hepatocytes

Wednesday 15:10-16:30

II-37Luzelena Caro

Population Pharmacokinetics Modeling Characterizes the Higher Grazoprevir Exposure in Japanese Compared to Non-Japanese HCV-Infected Patients

Wednesday 15:10-16:30

II-39Jason Cawley

Competitive brain and body growth model

Wednesday 15:10-16:30

II-46Maxwell Chirehwa

Semi-mechanistic pharmacokinetic model for Isoniazid and Acetyl isoniazid in a cohort of TB/HIV co-infected patients

Wednesday 15:10-16:30

II-51Pieter Colin

Propofol breath monitoring as a potential tool to improve the prediction of intraoperative plasma concentrations

Wednesday 15:10-16:30

II-65Wilbert de Witte

High drug-target association rates increase the duration of in vivo target occupancy

Wednesday 15:10-16:30

II-70Christiane Dings

Pharmacokinetic and Pharmacodynamic Modeling of Acetylsalicylic Acid and its Major Metabolite Salicylic Acid

Wednesday 15:10-16:30

II-74Erwin Dreesen

Anti-drug antibodies, low serum albumin and high C-reactive protein increase infliximab clearance in patients with inflammatory bowel disease: a population pharmacokinetic study of the TAXIT trial

Wednesday 15:10-16:30

II-77

Joint modelling of pain intensity and informative dropout in moderate to severe chronic pain patients

Wednesday 15:10-16:30

III-02Lia Liefaard

Mixed effects modelling of dose-response cough count data

Thursday 10:05-11:30

III-04Ling Xue

Theory based PK-PD of S- and R-warfarin: influence of body size, composition and genotype

Thursday 10:05-11:30

III-11Mats Magnusson

Population PKPD Analysis of CD4 and ACR Response after SC Administration of Tregalizumab to Patients with Rheumatoid Arthritis

Thursday 10:05-11:30

III-14Vikash Mansinghka

BayesDB Marcro Indicator Explorer ensemble models for growth outcome country phenotyping

Thursday 10:05-11:30

III-19Jean-Marie Martinez

Modelling and simulation of alirocumab – Part 1: Population pharmacokinetic analysis using a Michaelis-Menten approximation of the target-mediated drug disposition model

Thursday 10:05-11:30

III-26Pablo Morentin Gutierrez

A population pharmacokinetic-pharmacodynamic model for AZD7687: Effects on plasma triacylglycerol after oral lipid tolerance test

Thursday 10:05-11:30

III-30Zufar Muliukov

Modeling the effect of ranibizumab on central retinal thickness in patients with wet age-related macular degeneration

Thursday 10:05-11:30

III-34Xavier Nicolas

Modelling and simulation of alirocumab – Part 2: Population pharmacokinetic/pharmacodynamic analysis using an indirect response model to link drug concentrations with LDL-C

Thursday 10:05-11:30

III-35Jaeseong Oh

Simultaneous population pharmacokinetic analysis of VVZ-149 and its active metabolite in healthy volunteers

Thursday 10:05-11:30

III-36Boram Ohk

Population Pharmacokinetic modeling of Tacrolimus in Healthy Korean Subjects

Thursday 10:05-11:30

III-42- -

Delineation of the treatment effect of methotrexate when used in combination therapy for rheumatoid arthritis

Thursday 10:05-11:30

III-52Tatiana Petukhova

Population PK modeling of RPH-104, novel optimized IL-1 beta trap, and assessment of the immunogenicity effect on pharmacokinetics

Thursday 10:05-11:30

III-55Chiara Piana

A novel model-based methodology for the evaluation of abuse potential

Thursday 10:05-11:30

III-65Isabel Reinecke

Changes in endogenous estradiol concentrations explain fluctuations in levonorgestrel (LNG) concentrations during continuous treatment with LNG releasing intravaginal rings

Thursday 10:05-11:30

III-68Jakob Ribbing

Predicting reductions in chronic obstructive pulmonary disease (COPD) exacerbations from FEV1 – A model-based meta-analysis of literature data from controlled randomized clinical trials

Thursday 10:05-11:30

III-69Camille Riff

First population pharmacokinetic model of lidocaine tumescent anaesthesia in women undergoing breast cancer surgery

Thursday 10:05-11:30

III-72Stefan Roepcke

Model-based analysis of monkey PK and PD data of a therapeutic cell depleting human monoclonal antibody – Preparing for clinical trials

Thursday 10:05-11:30

IV-04Nina Scherer

Pharmacokinetic and Pharmacodynamic Modeling of Alirocumab and Evolocumab, two fully human monoclonal antibodies targeting PCSK9

Thursday 14:40-16:00

IV-11Victor Sokolov

A mechanistic PKPD model relating early asthmatic response to anti-leukotriene drug PK and biomarker levels in allergen challenge studies

Thursday 14:40-16:00

IV-14Konstantina Soulele

A population pharmacokinetic study of salmeterol in asthmatic patients using two dry powder inhalers

Thursday 14:40-16:00

IV-18Siddharth Sukumaran

A quantitative systems pharmacology model for evaluating potential drugs for treatment of asthma

Thursday 14:40-16:00

IV-22Tatiana Yakovleva

A systems pharmacology model of SGLT2 and SGLT1 inhibition to understand mechanism and quantification of urinary glucose excretion after treatment with Dapagliflozin, Canagliflozin and Empagliflozin

Thursday 14:40-16:00

IV-25Adrien Tessier

Population Pharmacokinetic modelling and Pharmacogenetic analysis through a penalised regression approach for a molecule S

Thursday 14:40-16:00

IV-47Coen van Hasselt

The proof is in the pee: Population asparagus urinary odor kinetics.

Thursday 14:40-16:00

IV-51Camille Vong

Population Pharmacokinetics of Tofacitinib in Induction Studies for Moderate-to-Severe Ulcerative Colitis Patients

Thursday 14:40-16:00

IV-59Thomas Wendl

Computational Modelling of Personalized Hemodynamic Response to Valve Replacement Surgery in Heart Failure Patients

Thursday 14:40-16:00

IV-65Dan Wright

A population pharmacokinetic model for 51Cr EDTA, an isotopic biomarker for renal function: impact on carboplatin dosing.

Thursday 14:40-16:00

IV-68

Pharmacokinetic Model for subconjunctival injection of bevacizumab in Rabbits.

Thursday 14:40-16:00

IV-72Fan Zhang

Population pharmacokinetic modeling of lamotrigine in Chinese subjects

Thursday 14:40-16:00

IV-77Kirill Zhudenkov

A Markov Chain model to characterize cataract progression and disease burden in the Russian Federation

Thursday 14:40-16:00